<DOC>
	<DOCNO>NCT01265667</DOCNO>
	<brief_summary>Eligible patient Psoriasis treat CF101 placebo twice daily 16 week . All subject receive open-lable CF101 week 17-32 .</brief_summary>
	<brief_title>Trial CF101 Treat Patients With Psoriasis</brief_title>
	<detailed_description>Eligible patient randomly assign parallel dose group CF101 2 mg match placebo tablet twice daily ( BID ) 1:1 ratio 16-week control treatment period . Approximately 94 patient assign group . Medication take orally BID 16 week double-blinded fashion . At end 16 week , patient assign CF101 continue CF101 , patient originally assign placebo reassign CF101 . Assessment peripheral blood mononuclear cell ( PBMC ) adenosine A3 receptor ( A3AR ) expression baseline treatment CF101 select site .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female , 18 80 year age , inclusive Diagnosis moderatetosevere chronic plaquetype psoriasis body surface area involvement ≥10 % Duration psoriasis least 6 month PGA ≥3 Candidate systemic treatment phototherapy psoriasis ECG normal Females childbearing potential must negative serum pregnancy test Females childbearing potential must willing use 2 method contraception Ability complete study compliance protocol Ability understand provide write informed consent . Erythrodermic , guttate , palmar , plantar , generalize pustular psoriasis Treatment systemic retinoids , corticosteroid , immunosuppressive agent within 4 week Baseline visit Treatment high potency topical corticosteroid , keratolytics , coal tar within 2 week Baseline visit Ultraviolet Dead Sea therapy within 4 week Baseline visit Treatment biological agent within period time equal 5 time circulate halflife Treatment lithium , hydroxychloroquine chloroquine within 2 week Baseline visit Serum creatinine level great 1.5 time laboratory 's upper limit normal Liver aminotransferase level great laboratory 's upper limit normal Significant acute chronic medical psychiatric illness Participation another investigational drug vaccine trial concurrently within 30 day prior Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque psoriasis</keyword>
</DOC>